Uso degli analoghi del GnRH nei bambini

1. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001;32:851-4. 2. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23. 3. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415-23. 4. Klein KO. Precocious puberty: who has it? Who should be treated? J Clin Endocrinol Metab 1999;84:411-4. 5. Lazar L, Pertzelan A, Weintrob N, Phillip M, Kauli R. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin- suppressive therapy and final height. J Clin Endocrinol Metab 2001;86:4127-32. 6. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin- suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-9. 7. Fontoura M, Brauner R, Prevot C, Rappaport R. Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 1989;64:1170-6. 8. Papadimitriou A, Beri D, Tsialla A, Fretzayas A, Psychou F, Nicolaidou P. Early growth acceleration in girls with idiopathic precocious puberty. J Pediatr 2006;149:43-6. 9. Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A. Bayley-Pinneau, Roche-Wainer- Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 1978;93:749- 55. 10. Bar A, Linder B, Sobel EH, Saenger P, Di- Martino-Nardi J. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J Pediatr 1995;126:955-8. 11. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997;47:54-61. 12. Heger S, Partsch CJ, Sippel WG. Longterm outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final body composition, bone mineral density and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90. 13. Carel JC, Roger M, Ispas S, et al. Final height after long-term treatment with triptorelin slow-release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999,84:1973-8. 14. Arrigo T, Cisternino M, De Luca F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999; 141:140-4. 15. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GBJ. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-6. 16. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near final height in 26 children with true precocius puberty treated at a median age less than 5 years. J Clin Endocrinol Metab 1995;80: 546-51. 17. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002;58:1-7. 18. Kaltiala-Heino R, Marttunen M, Rantanen P, Rimpela M. Early puberty is associated with mental health problems in middle adolescence. Soc Sci Med 2003;57:1055-64. 19. Albanese A, Hopper NW. Suppression of menstruation in adolescents with severe learning disabilities. Arch Dis Child 2007;92:629- 32. 20. Teilmann G, Boas M, Petersen JH, et al. Early pituitary-gonadal activation before clinical signs of puberty in 5- to 8-yearold adopted girls: a study of 99 foreign adopted girls and 93 controls. J Clin Endocrinol Metab 2007;92: 2538-44. 21. Teilmann G, Pedersen CB, Skakkebaek NE, Jensen TK. Increased risk of precocious puberty in internationally adopted children in Denmark. Pediatrics 2006;118:e391-9. 22. Tuvemo T, Jonsson B, Gustafsson J, et al. Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty. Acta Paediatr 2004; 93:1456-62. 23. Berg-Kelly K, Eriksson J. Adaptation of adopted foreign children at mid-adolescence as indicated by aspects of health and risk taking: a population study. Eur Child Adolesc Psychiatry 1997;6:199-206. 24. Mul D, Versluis-den Bieman HJ, Slijper FM, Oostdijk W, Waelkens JJ, Drop SL. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr 2001;90:965-71. 25. Neely EK, Hintz RL, Wilson DM, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127: 40-6. 26. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47-52. 27. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424-9. 28. Roger M, Lahlou N, Chaussain JL. Gonadotropin- releasing hormone testing in pediatrics. In: Ranke MB (Ed). Diagnostics of endocrine function in children and adolescents. Heidelberg: Johann Ambrosius Barth Verlag, 1996:346-69. 29. Eckert KL, Wilson DM, Bachrach LK, et al. A single-sample, subcutaneous gonadotropin- releasing hormone test for central precocious puberty. Pediatrics 1996;97:517-9. 30. Garibaldi LR, Aceto T Jr, Weber C, Pang S. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J Clin Endocrinol Metab 1993;76:851-6. 31. Ibanez L, Potau N, Zampolli M, et al. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test. J Clin Endocrinol Metab 1994;78:30-5. 32. Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB Jr. Premature thelarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing hormonereleasing hormone. J Clin Endocrinol Metab 1988;67:474-9. 33. Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251-8. 34. de Vries L, Horev G, Schwartz M, Phillip M. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol 2006;154:891-8. 35. Bay K, Andersson AM, Skakkebaek NE. Estradiol levels in prepubertal boys and girlsanalytical challenges. Int J Androl 2004;27:266- 73. 36. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography- tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534-43. 37. Battaglia C, Mancini F, Regnani G, Persico N, Iughetti L, De Aloysio D. Pelvic ultrasound and color Doppler findings in different isosexual precocities. Ultrasound Obstet Gynecol 2003;22:277-83. 38. Haber HP, Wollmann HA, Ranke MB. Pelvic ultrasonography: early differentiation between isolated premature thelarche and central precocious puberty. Eur J Pediatr 1995;154:182-6. 39. Chalumeau M, Hadjiathanasiou CG, Ng SM, et al. Selecting girls with precocious puberty for brain imaging: validation of European evidence-based diagnosis rule. J Pediatr 2003;143:445-50. 40. Cisternino M, Arrigo T, Pasquino AM, et al. Etiology and age incidence of precocious puberty in girls: a multicentric study. J Pediatr Endocrinol Metab 2000;13(Suppl 1):695- 701. 41. De Sanctis V, Corrias A, Rizzo V, et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):687-93. 42. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatric Drugs 2004;6:211-31. 43. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981;52:370-2. 44. Carel JC, Lahlou N, Guazzarotti L, et al. Treatment of central precocious puberty with depot leuprolide acetate. Eur J Endocrinol 1995;132:699-704. 45. Heinrichs C, Craen M, Vanderschueren- Lodeweyckx M, Malvaux P, Fawe L, Bourguignon JP. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depottriptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology. Acta Paediatr 1994;83:627-33. 46. Tuvemo T, Gustafsson J, Proos LA, and Swedish Growth Hormone Group. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Hormone Res 2002;57:27-31. 47. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13(Suppl 1):723-37. 48. Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 2002;16:165-89. 49. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61: 626-34. 50. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three- month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-7. 51. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007;92:1697-704. 52. Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798-802. 53. Tanaka T, Hibi I, Kato K, et al. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (Leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. Endocrinol Japn 1991;38:369-76. 54. Neely EK, Hintz RL, Parker B, et al. Twoyear results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992;121:634-40. 55. Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3- month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-6. 56. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Three-month sustainedrelease triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119-24. 57. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135-47. 58. Lee PA, Page JG, Group LS. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr 1989;114:321-4. 59. Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocius puberty. J Pediatr 1993;123: 334-5. 60. Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs 2002;11: 1253-9. 61. Schultze-Mosgau A, Griesinger G, Altgassen C, von Otte S, Hornung D, Diedrich K. New developments in the use of peptide gonadotropin- releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-97. 62. Eugster EA. Aromatase inhibitors in precocious puberty: rationale and experience to date. Treat Endocrinol 2004;3:141-51. 63. Lampit M, Golander A, Guttmann H, Hochberg Z. Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study. J Clin Endocrinol Metab 2002;87:687-90. 64. Vottero A, Pedori S, Verna M, et al. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab 2006;91:1284-7. 65. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999;84:449-52. 66. Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM. Effects of combined gonadotropin- releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab 2003;16:1005-10. 67. Oostdijk W, Rikken B, Schreuder S, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-7. 68. Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP- 144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005;90:1371-6. 69. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin- releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5. 70. Antoniazzi F, Arrigo T, Cisternino M, et al. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):773-80. 71. Mul D, Oostdijk W, Otten BJ, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13(Suppl 1):765-72. 72. Partsch CJ, Heger S, Sippell WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group. J Pediatr Endocrinol Metab 2000;13(Suppl 1):747-58. 73. Cassio A, Cacciari E, Balsamo A, Bal MO, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32. 74. Cassio A, Bal MO, Orsini LF, et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr 2006;149:532-6. 75. Feuillan PP, Jones JV, Barnes K, Oerter- Klein K, Cutler GBJ. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44-9. 76. Arrigo T, De Luca F, Antoniazzi F, et al. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment. Eur J Pediatr 2007; 166:73-4. 77. Heger S, Muller M, Ranke M, et al. Long term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-5:217-20. 78. Feuillan PP, Jones JV, Barnes KM, Oerter- Klein K, Cutler GB Jr. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin- releasing hormone analog therapy. J Clin Endocrinol Metab 2000;85:4036-8. 79. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000; 159:369-74. 80. Palmert MR, Mansfield MJ, Crowley WFJ, Crigler JFJ, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-8. 81. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506-12. 82. Antoniazzi F, Zamboni G, Bertoldo F, et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88:1096- 101. 83. Arrigo T, De Luca F, Antoniazzi F, et al. Reduction of baseline body mass index under gonadotropin- suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533-7. 84. Messaaoui A, Massa G, Tenoutasse S, et al. Treatment of central precocious puberty with gonadotropin-releasing hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment. Rev Med Brux 2005;6:27-32. 85. Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, Lorini R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463-4. 86. Lazar L, Kauli R, Pertzelan A, Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002;87:2090-4. 87. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998;157:363-7. 88. Escobar ME, Ropelato MG, Ballerini MG, et al. Acceleration of luteinizing hormone pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism. Horm Res 2007; 68:278-85. 89. Cisternino M, Pasquino A, Bozzola M, et al. Final height attainment and gonadal function in girls with precocious puberty treated with cyproterone acetate. Horm Res 1992; 3:86-90. 90. Palmert MR, Hayden DL, Mansfield MJ, et al. The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. J Clin Endocrinol Metab 2001;86:4536-42. 91. Jensen AM, Brocks V, Holm K, Laursen EM, Muller J. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropinreleasing hormone analogues. J Pediatr 1998; 132:105-8. 92. Rosenfield RL. Identifying children at risk of polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787-96. 93. Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A. High prevalence of abnormal adrenal response in girls with central precocious puberty at early pubertal stages. Eur J Endocrinol 1995;133:407-11. 94. Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 1995;133:403-6. 95. Steinberg L, Morris AS. Adolescent development. Annu Rev Psychol 2001;52:83-110. 96. Weichold K, Silbereisen RK, Schmitt-Rodermund E. Short-and long-term consequences of early versus late physical maturation in adolescents. In: Hayward C (Ed). Puberty and Psychopathology. Cambridge, MA: Cambridge University Press, 2003:241-76. 97. Susman EJ, Rogol AD. Puberty and psychological development. In: Lerner RM, Steinberg L (Eds). Handbook of Adolescent Psychology. 2nd ed. Hoboken, NJ: Wiley, 2004:15- 44. 98. Sisk CL, Zehr JL. Pubertal hormones organize the adolescent brain and behavior. Front Neuroendocrinol 2005;26:163-74. 99. Dorn LD. Psychological and social problems in children with premature adrenarche and precocious puberty. In: Pescovitz OH, Walvoord EC (Eds). When Puberty is Precocious: Scientific and Clinical Aspects. Totowa, NJ: Humana Press, 2007:309-27. 100. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 1997;86:808-15. 101. Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology 2006;31:935-47. 102. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391-7. 103. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987;19:159-62. 104. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31. 105. Antoniazzi F, Cisternino M, Nizzoli G, et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr 1994;83:1052-6. 106. Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL. Gonadotropin releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J Clin Endocrinol Metab 1996;81: 3318-22. 107. Bouvattier C, Coste J, Rodrigue D, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized longterm pilot study. J Clin Endocrinol Metab 1999;84:3575-8. 108. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003;348:908-17. 109. Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004;17:759-66. 110. Tuvemo T. Treatment of central precocious puberty. Expert Opin Investig Drugs 2006;15:495-505. 111. Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol Cell Endocrinol 2006;254-255:226-33. 112. Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 2000;85:619-22. 113. van Gool SA, Kamp GA, Visser-van Balen H, et al. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. J Clin Endocrinol Metab 2007;92:1402-8. 114. Mul D, Oostdijk W, Waelkens JJ, Drop SL. Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone. Clin Endocrinol (Oxf) 2005;63:185-90. 115. Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007;92:804-10. 116. Teng L, Bui H, Bachrach L, et al. Catch-up growth in severe juvenile hypothyroidism: treatment with a GnRH analog. J Pediatr Endocrinol Metab 2004;17:345-54. 117. Carel JC, Ecosse E, Nicolino M, et al. Adult height after long-term recombinant growth hormone treatment for idiopathic isolated growth hormone deficiency: observational follow-up study of the French populationbased registry. BMJ 2002;325:70-3. 118. Reiter EO, Lindberg A, Ranke MB, et al. The KIGS experience with the addition of gonadotropin- releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency. Horm Res 2003;60(suppl. 1):68-73. 119. Mul D, Wit JM, Oostdijk W, Van den Broeck J, and Dutch Advisory Group on Growth Hormone. The effect of pubertal delay by GnRH agonist in GH-deficient children on final height. J Clin Endocrinol Metab 2001; 86:4655-6. 120. Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 2000;85:569-73. 121. Saggese G, Federico G, Barsanti S, Fiore L. The effect of administering gonadotropinreleasing hormone agonist with recombinanthuman growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. J Clin Endocrinol Metab 2001;86:1900-4. 122. Tanaka T, Satoh M, Yasunaga T, et al. When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue. Acta Paediatr (Suppl) 1999;88:85-8. 123. Mericq V, Gajardo H, Eggers M, Avila A, Cassorla F. Effects of treatment with GH alone or in combination with LHRH analog on bone mineral density in pubertal GH-deficient patients. J Clin Endocrinol Metab 2002;87:84-9. 124. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005;90:3318-25. 125. Geier DA, Geier MR. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett 2006;27:833-8.